Sustained release formulations of NMDA antagonists containing encapsulated NMDA antagonist are described herein.

The present invention provides methods to prevent the formation of visible particles in aqueous protein formulations, as well as compositions and pharmaceutical products obtained with said method.

The invention relates to pharmaceutical compositions comprising a GLP-1 agonist, an SLGT2 inhibitor, a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, and a hydrotrope. The invention further relates to processes for the preparation of such compositions, and their use in medicine.

The disclosed invention relates to a low-dose celecoxib oral formulation, and a preparation method therefor, which is characterized in that the strength of the formulation is 60-90% of the original strength of the commercial celecoxib product, and the celecoxib formulation with such reduced strength is bioequivalent to the commercial celecoxib product. The celecoxib formulation can be used for the treatment of mild to moderate pain and mild to moderate chronic pain.

An orally administered solid dosage form drug for treating cancers, tumors or cell proliferative disorders contains a compound of the following structural formula I or II.

##STR00001##

Methods for producing large cannabinoid-loaded liposomes are provided. In one example, these liposomes are large and mostly multilamellar. In another example, the liposomes are a combination of large multilamellar and unilamellar liposomes.

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

The disclosure relates to a novel dosage form comprising hard gelatin capsule having granule composition, spray dried or evaporated composition containing tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine and tablet comprising tafamidis or its pharmaceutically acceptable salt particularly tafamidis meglumine that would not form a rigid gel upon contacting with water or buffer solution in dissolution specifically pH 6.8 phosphate buffer and that composition is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

A composition for use in a method for the treatment of an amino acid deficiency to a non-mammalian monogastric animal, such as a poultry animal, a fish or a crustacean is described, wherein said composition comprises (i) a mixture of active components comprising or, alternatively, consisting of at least one amino acid or an analogue, (ii) a lipid matrix embedding said (i) mixture of active components and, optionally, (iii) at least one acceptable pharmaceutical or food grade additive and/or excipient. Furthermore, a feed or feed additive for a non-mammalian monogastric animal, such as poultry species and/or aquatic species comprising the composition is also described.

The present invention relates to solid dispersions comprising a salt of ursolic acid with an alkali metal and a phospholipid and to oral dosage formulations containing them. The invention also relates to processes for preparing the solid dispersions and to the use of the solid dispersions and formulations for the prevention and/or treatment of a variety of pathological conditions in which hepatoprotective, antioxidant, anti-inflammatory, antiviral and cytotoxic activities are desired.